Format

Send to

Choose Destination
Oncology. 2003;64(3):227-31.

Selenium in breast cancer.

Author information

1
Department of Medicine, University of Cadiz School of Medicine, c/Dr. Marañón 6, E-11002 Cadiz, Spain. juanbosco.lopez@uca.es

Abstract

AIM:

Controversy surrounds the hypothetical relationship between low serum levels of selenium and reduced activity of selenium-dependent enzymes, such as glutathione peroxidase, and an increased risk of cancer in humans. This study investigated serum concentrations of selenium in women with and without breast cancer.

METHODS:

In this case-control study, we compared serum concentrations of selenium in women with breast cancer (n = 200), healthy women (n = 100), and women with chronic diseases (n = 100). Patients with breast cancer were divided into premenopausal (n = 99) and postmenopausal subjects (n = 101).

RESULTS:

Mean serum concentrations of selenium were 81.1 microg/l in women with breast cancer and 98.5 microg/l in women with non-tumoral disease (p < 0.001).

CONCLUSION:

Alterations in serum concentrations of selenium in women with breast cancer appear to be a consequence, rather than a cause of cancer. In accordance with the hypothesis, the findings suggest that very low selenium status could be due to the nature of cancer.

PMID:
12697962
DOI:
10.1159/000069312
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center